Nephrocare Health Services approves ESOP 2026 and INR 70 Cr Saudi collateral
Nephrocare Health Services Ltd approved the NephroPlus Employee Stock Option Scheme 2026, covering 20,06,814 options or 2% of paid-up capital, and sanctioned INR 70 Crore collateral support for its Saudi subsidiary, NephroPlus Kidney Services Company, replacing a prior approval for a joint venture entity.
*this image is generated using AI for illustrative purposes only.
Nephrocare Health Services Ltd has approved the NephroPlus Employee Stock Option Scheme 2026 and sanctioned collateral support of INR 70 Crore for its Saudi Arabian subsidiary to facilitate credit facilities. The Board of Directors granted these approvals at its meeting held on June 22, 2026. The ESOP 2026 will cover up to 20,06,814 options, representing approximately 2% of the company's paid-up equity share capital, while the financial support aims to enable the overseas step-down subsidiary to secure fund-based and non-fund-based credit facilities.
The NephroPlus Employee Stock Option Scheme 2026 was formulated in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the Companies Act, 2013. The Nomination and Remuneration Committee will administer the scheme, granting options to eligible employees of the company and its subsidiary, associate, and holding companies. Each option will confer the right to subscribe to one fully paid-up equity share with a face value of ₹2. The exercise price will be determined by the committee at the time of grant and may be equal to or lower than the prevailing market price, subject to specific vesting conditions if the discount exceeds 20%.
The collateral support of INR 70 Crore, or its equivalent in foreign currency, is provided in favour of NephroPlus Kidney Services Company, Kingdom of Saudi Arabia. This entity is an overseas step-down wholly owned subsidiary of nephrocare health services . The approval supersedes a previous resolution passed on May 19, 2026, which had authorized similar support for Nephrocare Health Services Saudi Arabia Company, a joint venture. The revision follows a proposed change in the funding, ownership, and operating structure for the Saudi operations.
Key Details of ESOP 2026
| Particulars | Details |
|---|---|
| Total Options | 20,06,814 |
| Shares Covered | 20,06,814 equity shares |
| Percentage of Paid-up Capital | 2% |
| Face Value | ₹2 per share |
| Vesting Period | Minimum 1 year, up to 4 years |
| Exercise Period | Up to 5 years from vesting |
Vested options may be exercised within a period of up to five years from the respective date of vesting. The scheme includes provisions for the treatment of options in events such as resignation, termination, death, and corporate actions. All grants and exercises will be subject to applicable regulatory and statutory approvals.
Historical Stock Returns for Nephrocare Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.51% | -8.53% | +11.89% | +46.66% | +44.24% | +44.24% |
What specific strategic benefits does the shift from a joint venture to a wholly owned subsidiary offer Nephrocare in the Saudi Arabian market?
How will the infusion of INR 70 Crore in credit facilities specifically impact the expansion capacity of NephroPlus Kidney Services in the Kingdom?
What criteria will the Nomination and Remuneration Committee use to determine the exercise price, particularly if a discount exceeding 20% is applied?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
